Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TECX Stock Forecast 2026-2027
$32.60
Current Price
$656.84M
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TECX Price Targets
+209.8%
To High Target of $101.00
+145.4%
To Median Target of $80.00
+84.0%
To Low Target of $60.00
TECX Price Momentum
-5.1%
1 Week Change
+8.6%
1 Month Change
+48.8%
1 Year Change
+56.3%
Year-to-Date Change
-17.5%
From 52W High of $39.53
+126.5%
From 52W Low of $14.39
📊 TOP ANALYST CALLS
Did TECX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tectonic Therapeutics is one of their latest high-conviction picks.
Latest TECX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, TECX has a bullish consensus with a median price target of $80.00 (ranging from $60.00 to $101.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $32.60, the median forecast implies a 145.4% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TECX Analyst Ratings
10
Buy
0
Hold
0
Sell
TECX Price Target Range
Low
$60.00
Average
$80.00
High
$101.00
Current: $32.60
Latest TECX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TECX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 26, 2026 | Raymond James | Michael Freeman | Strong Buy | Upgrade | $81.00 |
| Apr 14, 2026 | Stifel | Buy | Initiates | $N/A | |
| Jan 8, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Sep 3, 2025 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jul 21, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Jun 11, 2025 | Raymond James | Michael Freeman | Outperform | Reinstates | $76.00 |
| Jun 6, 2025 | LifeSci Capital | Outperform | Initiates | $N/A | |
| May 15, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Apr 21, 2025 | Mizuho | Outperform | Initiates | $N/A | |
| Mar 21, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Jan 31, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Nov 20, 2024 | Raymond James | Outperform | Initiates | $N/A | |
| Nov 12, 2024 | Wells Fargo | Overweight | Maintains | $N/A | |
| Nov 11, 2024 | Leerink Partners | Outperform | Maintains | $N/A | |
| Aug 22, 2024 | Wells Fargo | Overweight | Initiates | $N/A | |
| Jul 24, 2024 | Leerink Partners | Outperform | Initiates | $N/A | |
| Jun 26, 2024 | Piper Sandler | Overweight | Initiates | $N/A | |
| Jun 24, 2024 | TD Cowen | Buy | Initiates | $N/A |
Tectonic Therapeutic Inc. (TECX) Competitors
The following stocks are similar to Tectonic Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TECX
Tectonic Therapeutics
mkt cap
648.53M
Tectonic Therapeutic Inc. (TECX) Financial Data
Tectonic Therapeutic Inc. has a market capitalization of $656.84M with a P/E ratio of 4.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.4%.
Valuation Metrics
Market Cap
$656.84M
Enterprise Value
$416.27M
P/E Ratio
4.6x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+38.5%
Current Ratio
18.5x
Debt/Equity
2.0x
ROE
-31.4%
ROA
-20.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tectonic Therapeutic Inc. (TECX) Business Model
About Tectonic Therapeutic Inc.
What They Do
Develops innovative biopharmaceutical therapies.
Business Model
The company generates revenue through the discovery and development of transformative therapies that address unmet medical needs. By utilizing advanced technology platforms, Tectonic Therapeutic creates tailored drugs that enhance treatment efficacy and reduce side effects. Collaborations with research institutions and industry partners further accelerate the development of its therapeutic programs.
Additional Information
Tectonic Therapeutic is influential in the biotechnology and healthcare sectors, contributing to improved patient outcomes and offering new solutions for complex diseases. Its commitment to innovation positions it as a significant player in the medical biotechnology market, attracting attention from investors and stakeholders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
60
CEO
Dr. Alise S. Reicin M.D., Ph.D.
Country
United States
IPO Year
2018
Website
tectonictx.comTectonic Therapeutic Inc. (TECX) Latest News & Analysis
Latest News
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
1 month ago
Quick Summary
Tectonic Therapeutic (NASDAQ: TECX) has completed enrollment for the APEX trial, a Phase 2 study assessing TX45 for pulmonary hypertension related to heart failure.
Why It Matters
Completion of enrollment in the APEX trial for TX45 could lead to significant advancements in treating pulmonary hypertension, potentially boosting Tectonic's stock value and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
2 months ago
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) reported Q1 2026 financial results and shared recent business developments focused on therapeutic proteins and GPCRs.
Why It Matters
Tectonic Therapeutic's Q1 financial results and business updates signal its progress in biotech, impacting investor sentiment and potential stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. The company focuses on therapeutic proteins and antibodies targeting GPCRs.
Why It Matters
The appointment of Jessica Chutter to Tectonic's Board may signal strategic changes or enhanced governance, potentially impacting investor confidence and future company performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tectonic Therapeutics is advancing TX45 for Group 2 Pulmonary Hypertension, backed by strong phase 1b data. With $253.8M in cash, it's positioned for phase 2; potential U.S. peak sales of $0.6B–$1.8B by 2026.
Why It Matters
Tectonic Therapeutic's TX45 targets a large market with promising phase 1b data, offering potential for significant future sales. Its strong cash position supports continued development.
Source: Seeking Alpha
Market Sentiment:
Positive
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
4 months ago
Quick Summary
Tectonic Therapeutic, Inc. (TECX) presented at the TD Cowen 46th Annual Health Care Conference, providing updates on its developments and strategies.
Why It Matters
Tectonic Therapeutics' presentation may signal key developments in their pipeline, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
4 months ago
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) reported its financial results for Q4 and full year 2025, focusing on therapeutic proteins and antibodies targeting GPCRs.
Why It Matters
Tectonic Therapeutic's financial results and business highlights indicate its progress and potential in the biotech sector, influencing investor sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TECX Stock
What is Tectonic Therapeutic Inc.'s (TECX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Tectonic Therapeutic Inc. (TECX) has a median price target of $80.00. The highest price target is $101.00 and the lowest is $60.00.
Is TECX stock a good investment in 2027?
According to current analyst ratings, TECX has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $32.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TECX stock?
Wall Street analysts predict TECX stock could reach $80.00 in the next 12 months. This represents a 145.4% increase from the current price of $32.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tectonic Therapeutic Inc.'s business model?
The company generates revenue through the discovery and development of transformative therapies that address unmet medical needs. By utilizing advanced technology platforms, Tectonic Therapeutic creates tailored drugs that enhance treatment efficacy and reduce side effects. Collaborations with research institutions and industry partners further accelerate the development of its therapeutic programs.
What is the highest forecasted price for TECX Tectonic Therapeutic Inc.?
The highest price target for TECX is $101.00 from at , which represents a 209.8% increase from the current price of $32.60.
What is the lowest forecasted price for TECX Tectonic Therapeutic Inc.?
The lowest price target for TECX is $60.00 from at , which represents a 84.0% increase from the current price of $32.60.
What is the overall TECX consensus from analysts for Tectonic Therapeutic Inc.?
The overall analyst consensus for TECX is bullish. Out of 2 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $80.00.
How accurate are TECX stock price projections?
Stock price projections, including those for Tectonic Therapeutic Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 3:01 AM UTC